Geovax Labs Risk Profile Appears Stable, But Investors Should Watch for Emerging SEC-Disclosed PressuresTip Ranks·Jul 29 at 01:00 AMGOVX-265.00%GOVXW0.00%
GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q SummaryTradingView·Jul 27 at 03:41 PMGOVX-265.00%GOVXW0.00%
GeoVax Q2 FY26 net loss narrows to $4.43 million, or $0.97 a share; revenue posts no revenuePUBT·Jul 27 at 03:34 PMGOVXW0.00%GOVX-265.00%
GeoVax gets Nasdaq notice for failing $2.5 million stockholders’ equity requirementPUBT·Jul 10 at 03:06 PMGOVXW0.00%GOVX-265.00%
GeoVax Labs shareholders approve Wipfli as independent auditor for 2026PUBT·Jun 17 at 03:33 PMGOVXW0.00%GOVX-265.00%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 1 at 07:06 AMGOVX-265.00%AIM+783.00%
Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watchnasdaq·May 26 at 03:00 AMAKTX-372.00%SLGL+415.00%
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga_article·May 22 at 07:06 AMQTEX+286.00%MTVA+205.00%
Biotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalystsrttnews·May 21 at 09:40 PMAKTX-372.00%PIII-202.00%
GeoVax Labs shares are trading higher after the company highlighted the potential role of modified vaccinia Ankara-based vaccine tools in combatting hemorrhagic fever threats such as those caused by Ebola.benzinga_article·May 20 at 12:28 PMGOVXW0.00%GOVX-265.00%
GeoVax Raises $2.7 Million Net in Private Placement of Pre-Funded and Common WarrantsTradingView·May 19 at 04:13 PMGOVXW0.00%GOVX-265.00%
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease ThreatsEQS·May 18 at 01:33 PMGOVX-265.00%IBB+87.00%
GeoVax Reports Q1 2026 Net Loss $5.3M, Cash $1.3M, Advances GEO-MVA Phase 3 PlansTradingView·May 14 at 03:33 PMGOVX-265.00%GOVXW0.00%
